WallStSmart

The Ensign Group Inc (ENSG)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

The Ensign Group Inc generates 478% more annual revenue ($5.06B vs $875.26M). NUTX leads profitability with a 8.1% profit margin vs 6.8%. NUTX trades at a lower P/E of 9.1x. ENSG earns a higher WallStSmart Score of 57/100 (C).

ENSG

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.34

NUTX

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 9.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ENSGFair Value (-0.3%)

Margin of Safety

-0.3%

Fair Value

$211.28

Current Price

$203.89

$7.39 premium

UndervaluedFair: $211.28Overvalued
NUTXSignificantly Overvalued (-44.5%)

Margin of Safety

-44.5%

Fair Value

$71.26

Current Price

$100.38

$29.12 premium

UndervaluedFair: $71.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.2%8/10

Revenue surging 20.2% year-over-year

NUTX4 strengths · Avg: 9.5/10
P/E RatioValuation
9.1x10/10

Attractively priced relative to earnings

Return on EquityProfitability
58.9%10/10

Every $100 of equity generates 59 in profit

Operating MarginProfitability
97.5%10/10

Strong operational efficiency at 97.5%

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Areas to Watch

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.784/10

Expensive relative to growth rate

P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Profit MarginProfitability
6.8%3/10

6.8% margin — thin

NUTX3 concerns · Avg: 2.3/10
Market CapQuality
$671.69M3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-41.1%2/10

Revenue declined 41.1%

EPS GrowthGrowth
-86.2%2/10

Earnings declined 86.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 20.2% demonstrates continued momentum.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Return on Equity, Operating Margin.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ENSG profiles as a growth stock while NUTX is a value play — different risk/reward profiles.

NUTX carries more volatility with a beta of 2.00 — expect wider price swings.

ENSG is growing revenue faster at 20.2% — sustainability is the question.

ENSG generates stronger free cash flow (133M), providing more financial flexibility.

Bottom Line

ENSG scores higher overall (57/100 vs 55/100) and 20.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?